Treatment for Cannabis Withdrawal and Dependence

Exclusion Criteria

• •Abstinent from cannabis more than 2 days at the time of randomization
• •Currently meets DSM IV criteria for dependence on substances, or has urine drug screen positive for substances, other than cannabis or nicotine
• •Meets DSM IV criteria for a major AXIS I disorder other than cannabis and nicotine dependence,
• •Active suicidal ideation
• •Significant medical disorders that will increase potential risk or interfere with study participation,
• •Females who are pregnant, nursing or who are sexually active with child-bearing potential and refuse to use a double-barrier method of birth control during the study and for up to 4 weeks after study termination
• •Ongoing treatment with medications that may affect study outcomes,
• •Use of CYP3A4 strong inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) and CYP3A4 moderate inhibitors (e.g., diltiazem) within the 2 week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
• •Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
• •Ongoing treatment with medications that are primarily metabolized by CYP3A4 and may have increased plasma concentrations when co-administered with aprepitant, such as pimozide, terfenadine, astemizole or cisapride or corticosteroids, as well as benzodiazepines including midazolam, alprazolam, and triazolam.
• •Ongoing treatment with medications that are primarily metabolized by CYP2C9 (e.g., warfarin, tolbutamide).
• •Use of drugs (e.g., rifampin, carbamazepine, phenytoin) or herbal supplements (e.g., St John's wort) that induce CYP3A4 activity and may result in reduced plasma concentrations of aprepitant and decreased efficacy of aprepitant.
• •Inability to understand and/or comply with the provisions of the protocol and consent form.